FDA v. Brown & Williamson Tobacco Corp.

FDA v. Brown & Williamson Tobacco Corp.
Case name	FDA v. Brown & Williamson Tobacco Corp.
Citation	529 U.S. 120 (2000)
Court	Supreme Court of the United States
Decided	January 7, 2000
Docket	No. 99-110
Prior	Judgment for petitioners, United States Court of Appeals for the District of Columbia Circuit
Holding	The Food and Drug Administration lacks authority under the Federal Food, Drug, and Cosmetic Act to regulate tobacco products as "drugs" or "devices."
Majority	Sandra Day O'Connor
Joinmajority	William Rehnquist, John Paul Stevens, Antonin Scalia, Anthony Kennedy, David Souter, Clarence Thomas, Stephen Breyer
Concurrence	Ruth Bader Ginsburg

FDA v. Brown & Williamson Tobacco Corp.

FDA v. Brown & Williamson Tobacco Corp. is a landmark 2000 decision of the Supreme Court of the United States holding that the Food and Drug Administration does not have statutory authority under the Federal Food, Drug, and Cosmetic Act to regulate tobacco products as "drugs" or "devices." The case resolved a dispute involving tobacco companies, including Brown & Williamson Tobacco Corporation, public health advocates, and multiple federal agencies about the scope of the Food and Drug Administration's regulatory reach. The Court's ruling shaped later legislative action and administrative policy concerning tobacco control, public health law, and administrative law.

Background

Litigation began after the Food and Drug Administration issued a 1996 notice proposing that nicotine and tobacco products could be regulated as "drugs" or "devices" under the Federal Food, Drug, and Cosmetic Act; the notice followed David Kessler's tenure as FDA Commissioner and enforcement efforts. Plaintiffs included tobacco manufacturers such as Brown & Williamson Tobacco Corporation, Philip Morris USA, and trade associations like the Tobacco Institute and Council for Tobacco Research; they sought declaratory and injunctive relief in the United States District Court for the District of Columbia. The United States Department of Health and Human Services and the Office of Management and Budget figures appeared in related regulatory debates; amici included public health organizations such as the American Medical Association, the American Cancer Society, and the Campaign for Tobacco-Free Kids. Prior litigation and settlements, including the Master Settlement Agreement (1998) and state civil litigation led by state Attorneys General like Janet Reno and Eliot Spitzer-initiated actions, contextualized the dispute.

Legal Questions

The Supreme Court addressed whether the Food and Drug Administration has statutory authority under the Federal Food, Drug, and Cosmetic Act to regulate tobacco products and nicotine as "drugs" or "devices." The case presented subsidiary questions about the Administrative Procedure Act, separation of powers principles involving Congress and executive agencies such as the Department of Health and Human Services, and the extent to which Congress had implicitly precluded FDA regulation through statutes like the Federal Cigarette Labeling and Advertising Act and subsequent amendments. The Court weighed interpretive canons from precedents including Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc., United States v. Mead Corp., and Auer v. Robbins.

Supreme Court Decision

In a majority opinion authored by Sandra Day O'Connor, the Court held that the Food and Drug Administration cannot regulate tobacco products as "drugs" or "devices" under the Federal Food, Drug, and Cosmetic Act. The decision reversed the judgment of the United States Court of Appeals for the District of Columbia Circuit and remanded with instructions to enter judgment for the tobacco companies. Justice Ruth Bader Ginsburg concurred in the judgment but wrote separately to stress different aspects of statutory construction and deference. The ruling was decided during the Rehnquist Court term and carried an 8–1 alignment on the statutory question with nuanced views on administrative deference.

Reasoning and Legal Analysis

The Court applied traditional tools of statutory interpretation, examining text, structure, and legislative history. It found that Congress had enacted a comprehensive scheme through laws such as the Federal Cigarette Labeling and Advertising Act of 1965 and the Comprehensive Smoking Education Act of 1984 that implicitly left regulation of tobacco to Congress and the Legislative Branch's clear prescriptions. The majority invoked precedents like Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc. for questions of agency deference but concluded that even if deference applied, the FDA's assertion of authority was foreclosed by the statutory context. The opinion surveyed public policy developments, referencing Congressional hearings involving lawmakers such as Orrin Hatch and Tom Harkin, public reports from the Surgeon General of the United States, and regulatory actions by the Federal Trade Commission. The Court emphasized that granting FDA regulatory authority over tobacco would have major economic, social, and political consequences beyond typical agency expertise, and that Congress—through measures like the Synar Amendment and appropriations riders—had repeatedly acted on tobacco specifically.

Impact and Aftermath

The decision significantly constrained administrative law doctrine concerning the scope of agency authority and influenced litigation strategy by public health advocates and private litigants. It altered regulatory trajectories at the Food and Drug Administration and prompted intensified legislative activity in the United States Congress culminating in comprehensive statutory reform. The ruling intersected with global tobacco control initiatives, including the World Health Organization's Framework Convention on Tobacco Control, and affected litigation such as subsequent cases against tobacco companies in state courts and federal venues like the United States Court of Appeals for the Ninth Circuit. Public health organizations including the Centers for Disease Control and Prevention and the World Bank responded with policy analyses and recommendations.

Legislative and Regulatory Responses

In direct response, Congress enacted the Family Smoking Prevention and Tobacco Control Act of 2009, sponsored by legislators including John Dingell and Henry Waxman, granting the Food and Drug Administration explicit authority to regulate tobacco products, set standards, and oversee marketing and labeling. The act amended the Federal Food, Drug, and Cosmetic Act to create a specific regulatory regime for tobacco and authorized rulemaking affecting manufacturers such as Altria Group, Inc. and RJ Reynolds Tobacco Company. The FDA subsequently issued rules and guidance concerning product standards, cessation aids, and youth access enforcement, interfacing with agencies like the Federal Trade Commission and states' Attorneys General. The case remains a touchstone in discussions of statutory interpretation, agency power, and public health regulation, cited in later Supreme Court opinions and administrative decisions concerning delegated authority.

Category:United States Supreme Court cases